Key result
DeVega's tricuspid annuloplasty during mitral valve replacement increased the rate of trace or less tricuspid regurgitation at 3 months compared to replacement alone (47.8% vs 25.0%; p<0.05).
Why the study?
Does DeVega's tricuspid annuloplasty improve tricuspid regurgitation severity in patients with moderate secondary tricuspid regurgitation undergoing mitral valve replacement?
Cohort (n=43)
Does DeVega's tricuspid annuloplasty improve tricuspid regurgitation severity in patients with moderate secondary tricuspid regurgitation undergoing mitral valve replacement?
Absolute Event Rate: 47.8% vs 25%
p-value: p=<0.05
DeVega's tricuspid annuloplasty during mitral valve replacement for rheumatic heart disease significantly increases the proportion of patients achieving trace or less tricuspid regurgitation at 3 months compared to mitral valve replacement alone.
May support adjunctive annuloplasty for moderate secondary TR; leaves open need for RCTs before practice change.
BACKGROUND: Moderate secondary tricuspid incompetence has variable natural history if left unattended during mitral valve surgery. Recent data suggest progression of the secondary tricuspid incompetence over time.Secondary moderate tricuspid regurgitation in rheumatic mitral valve disease may regress after mitral valve surgery without direct intervention. OBJECTIVES: The present study was done to assess early result of DeVega tricuspid valve annuloplasty amongst those with moderate tricuspid regurgitation due to rheumatic mitral valve disease. METHODS: Group I(mitral value replacement with tricuspid repair) and group II (mitral value replacement only).The two groups were followed up at three months post-operatively and evaluated for their functional class and echocardiography variables. RESULTS: There were 43 patients who underwent mitral valve replacement with moderate tricuspid regurgitation. 23 underwent mitral valve replacement with tricuspid repair group (Group 1). Most of the patients were women (28/43). The mean age was 31.4 + 14.8 and 25.13 + 9.4 years. Group I had 21(91.3%) and Group II had 17 (85%) in NYHA class III and IV. The pre-operative echocardiographic cardiac left ventricular and left atrial dimensions, Left ventricular function and valve lesions were statistically similar for both groups, except PASP was higher amongst tricuspid repair (Group 1: 38.60 + 12.75 mHg, Group 2: 61.52 + 19.76 mmHg; p equals or less than 0.05). At three month review after surgery, four patients were in NYHA II amongst those without tricuspid repair (Group II), whilst the rest were in NYHA I. Left ventricular dimensions, Left Ventricular function and valve prosthetic valve function were similar between groups. Eleven (47.8%) patients in Group I and only five (25%) of Group II had trace or less TR at the follow-up. This was found to be statistically significant on chi square test (p less than 0.05). There were 7 (16.2%) patients who had persistent moderate TR. Higher PASP and larger LV dimensions at three months were predictive of persistent moderate TR. CONCLUSION: Mitral valve replacement does decrease the severity of tricuspid regurgitation amongst those with secondary moderate tricuspid regurgitation by at least one grade, but DeVega's annuloplasty confers a better repair result.
No takes yet. Share an insight, caveat, or question.
Pradhan et al. (2012) conducted a cohort in Moderate secondary tricuspid regurgitation due to rheumatic mitral valve disease (n=43). DeVega tricuspid valve annuloplasty vs. Mitral valve replacement only was evaluated on Trace or less tricuspid regurgitation at 3 months (p=<0.05). DeVega's tricuspid annuloplasty during mitral valve replacement increased the rate of trace or less tricuspid regurgitation at 3 months compared to replacement alone (47.8% vs 25.0%; p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: